Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

Merrill Lynch Names MedImmune as Focus One Stock of the Week


Merrill Lynch named MedImmune (MEDI) as the Focus One stock of the week, and reiterates its near-term and long-term buy rating.

Analyst Eric Hecht says the company's Synagis continues to do well; he expects worldwide Synagis sales to grow 15%-20% over the next three years, providing a strong contribution to his 30%-35% underlying earnings per share growth rate assumption.

Hecht says he's confident that FluMist will receive FDA approval and be launched in time for the 2002-2003 flu season; he sees the potential for MedImmune to achieve $750 million to $1 billion in peak sales.

He notes the pipeline remains strong, with five products in the late stages of development. Hecht says on a price-earnings-to-growht basis, MedImmune currently is the least expensive stock in his universe. He has a $70 12-month target.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus